Citius (CTXR) Announces Results of Mino-Lok Study.
"Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected...
Dalrada (DFCO) Announces Form S-1 Registration Declared Effective by SEC
SAN DIEGO , Nov. 3, 2020 /PRNewswire/ -- Dalrada Financial Corp. (OTC Pink: DFCO), is pleased to announce that its Form S-1 registration statement has been declared...
Telehealth App Hapbee (HAPB) Goes Public and More.
1. Hapbee (HAPB) $0.30, Going Public.2. Saying Goodbye to Immunomedics (IMMU) $86.3. Adding Biosig (BSGM) $2.95, to Watch...
Dalrada Cervical Cancer Testing Kit Study.
KEY TAKEAWAYS
Dalrada Corp (DFCO)
LIVE QUOTE
Dalrada’s ‘VIA’ Test Screening Kit Goes Head to Head with ‘Pap’ Smear Test Screening.
DALRADA aims to introduce its VIA Test kit to females in India - of which there is 497 million.
Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.
2021 and 2020 Milestones In Plain Sight.
Locked and Loaded for most of 2020 - many major milestone...
Citius Pharma (CTXR) Video Presentation.
Chairman Leonard Mazur Discusses:
Mino-Lok Treatment for Infected Catheters.
Novellus Stem Cell Treatment...
American BriVision’s (ABVC) Clinical Study Sparks Interest From Potential Partners.
Is Wall Street Missing American Brivision's Full Clinical Safety and Efficacy Study? We Think it has.
Potential...
There’s Simply No Loyalty Anymore.
TODAY'S LETTER
Frontier Bio (FBIO) $3.90. We Have Another Double! American BriVision (ABVC) $4.00. Wait, What? Yet...
And We Have Another Double. Frontier Bio (FBIO) Crosses $4.00.
Sometimes we Can't Beleive Our Luck Over the Last Couple Years. But There You Have it, at Least we Know It's...